Show
Sort by
-
Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent
-
Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights
-
Expression of hexokinases and glucose transporters in treated and untreated oesophageal adenocarcinoma
-
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: An experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy
-
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with 3 different contrast agents for therapy monitoring in a tumour bearing mouse model.
-
Expression of SGLT1 and Bcl-2 in panreatic cancer and their metastases related to survival.
-
Functionele beeldvorming van respons op anti-angiogene therapie
(2008) Up to date. -
Expression of hexokinase II in pancreatic cancer predicts survival
-
Expression of SGLT1 and Bcl-2 in pancreatic cancer and their metastases related to survival
-
Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival